Stock listing
NASDAQ:SANA Sana Biotechnology, Inc. Stock
Home listing (NASDAQ) of Sana Biotechnology, Inc.
Follow Sana Biotechnology, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:SANA
$1.59 USD -0.26 (-14.1%)
Close on Nov 20, 2026
- Day range
- $1.57 – $1.75 USDNov 20, 2026
- Volume
- 4.45M sharesNov 20, 2026
- Market cap
- $476.4M USDAt the close on Nov 20, 2026 · price × 299.6M shares outstanding
- 52-week range
- $1.57 – $5.49 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $9.33M USDMedian day 2.92M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:SANA · Home | $1.59 USD | -0.26 (-14.1%) | 4,452,514 | $1.70 | $1.75 | $1.565 | $1.85 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:SANA · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $1.59 | -0.26 | -14.1% | $1.70 | $1.75 | $1.565 | 4,452,514 | |
| $1.85 | -0.03 | -1.6% | $1.86 | $1.995 | $1.841 | 2,659,158 | |
| $1.88 | 0.00 | 0.0% | $1.88 | $1.92 | $1.84 | 2,632,278 | |
| $1.88 | -0.14 | -6.9% | $1.99 | $2.019 | $1.87 | 4,343,900 | |
| $2.02 | +0.01 | +0.5% | $2.05 | $2.05 | $1.86 | 3,195,306 | |
| $2.01 | -0.28 | -12.2% | $2.25 | $2.25 | $2.00 | 3,665,134 | |
| $2.29 | -0.14 | -5.8% | $2.43 | $2.449 | $2.28 | 2,710,924 | |
| $2.43 | -0.035 | -1.4% | $2.42 | $2.52 | $2.315 | 2,533,522 | |
| $2.465 | +0.095 | +4.0% | $2.45 | $2.48 | $2.28 | 3,259,857 | |
| $2.37 | +0.03 | +1.3% | $2.49 | $2.49 | $2.283 | 2,288,241 | |
| $2.34 | -0.22 | -8.6% | $2.53 | $2.53 | $2.28 | 3,066,256 | |
| $2.56 | +0.12 | +4.9% | $2.55 | $2.62 | $2.455 | 2,627,698 | |
| $2.44 | +0.04 | +1.7% | $2.43 | $2.52 | $2.40 | 1,818,638 | |
| $2.40 | -0.17 | -6.6% | $2.57 | $2.585 | $2.37 | 2,594,455 | |
| $2.57 | -0.15 | -5.5% | $2.68 | $2.72 | $2.51 | 2,075,932 | |
| $2.72 | +0.09 | +3.4% | $2.65 | $2.768 | $2.65 | 3,307,850 | |
| $2.63 | +0.16 | +6.5% | $2.43 | $2.64 | $2.38 | 3,273,499 | |
| $2.47 | +0.11 | +4.7% | $2.37 | $2.48 | $2.33 | 2,619,899 | |
| $2.36 | +0.03 | +1.3% | $2.33 | $2.385 | $2.29 | 1,509,332 | |
| $2.33 | -0.04 | -1.7% | $2.35 | $2.38 | $2.245 | 1,707,921 | |
| $2.37 | +0.02 | +0.9% | $2.31 | $2.44 | $2.28 | 2,427,176 | |
| $2.35 | -0.01 | -0.4% | $2.38 | $2.39 | $2.315 | 2,395,417 | |
| $2.36 | +0.06 | +2.6% | $2.27 | $2.42 | $2.25 | 3,487,153 | |
| $2.30 | +0.03 | +1.3% | $2.32 | $2.359 | $2.225 | 2,606,588 | |
| $2.27 | -0.205 | -8.3% | $2.46 | $2.51 | $2.25 | 3,088,800 | |
| $2.475 | +0.145 | +6.2% | $2.36 | $2.51 | $2.35 | 2,916,200 | |
| $2.33 | -0.08 | -3.3% | $2.37 | $2.43 | $2.32 | 2,762,300 | |
| $2.41 | -0.21 | -8.0% | $2.60 | $2.635 | $2.37 | 4,903,600 | |
| $2.62 | -0.17 | -6.1% | $2.77 | $2.77 | $2.59 | 2,669,300 | |
| $2.79 | 0.00 | 0.0% | $2.79 | $2.87 | $2.77 | 2,918,200 | |
| $2.79 | +0.07 | +2.6% | $2.72 | $2.81 | $2.66 | 4,514,100 | |
| $2.72 | -0.03 | -1.1% | $2.71 | $2.845 | $2.70 | 4,314,700 | |
| $2.75 | -0.13 | -4.5% | $2.94 | $2.975 | $2.74 | 3,759,400 | |
| $2.88 | -0.01 | -0.3% | $2.90 | $2.93 | $2.82 | 5,391,800 | |
| $2.89 | 0.00 | 0.0% | $2.95 | $3.00 | $2.855 | 3,495,300 | |
| $2.89 | -0.025 | -0.9% | $2.89 | $3.05 | $2.85 | 3,762,200 | |
| $2.915 | +0.005 | +0.2% | $2.97 | $3.045 | $2.855 | 3,245,600 | |
| $2.91 | -0.02 | -0.7% | $2.945 | $3.055 | $2.89 | 3,042,800 | |
| $2.93 | -0.015 | -0.5% | $2.92 | $2.98 | $2.86 | 2,264,400 | |
| $2.945 | -0.015 | -0.5% | $2.96 | $3.00 | $2.90 | 2,880,200 | |
| $2.96 | -0.12 | -3.9% | $3.04 | $3.047 | $2.88 | 3,505,800 | |
| $3.08 | -0.25 | -7.5% | $3.33 | $3.33 | $3.014 | 3,835,400 | |
| $3.33 | +0.23 | +7.4% | $3.15 | $3.36 | $3.10 | 7,167,600 | |
| $3.10 | 0.00 | 0.0% | $3.14 | $3.16 | $3.04 | 2,004,400 | |
| $3.10 | 0.00 | 0.0% | $3.09 | $3.11 | $3.02 | 7,408,800 | |
| $3.10 | +0.18 | +6.2% | $3.08 | $3.275 | $3.055 | 2,916,000 | |
| $2.92 | -0.24 | -7.6% | $3.17 | $3.21 | $2.865 | 9,724,400 | |
| $3.16 | -0.04 | -1.3% | $3.20 | $3.20 | $3.075 | 2,468,400 | |
| $3.20 | +0.07 | +2.2% | $3.135 | $3.25 | $3.10 | 2,378,800 | |
| $3.13 | +0.04 | +1.3% | $3.13 | $3.165 | $3.01 | 3,278,900 | |
| $3.09 | -0.08 | -2.5% | $3.10 | $3.19 | $3.00 | 4,616,100 | |
| $3.17 | -0.28 | -8.1% | $3.51 | $3.525 | $3.16 | 8,650,600 | |
| $3.45 | -0.40 | -10.4% | $3.78 | $3.83 | $3.395 | 4,986,000 | |
| $3.85 | -0.07 | -1.8% | $3.86 | $3.915 | $3.81 | 1,239,200 | |
| $3.92 | +0.03 | +0.8% | $3.93 | $3.96 | $3.80 | 2,637,200 | |
| $3.89 | +0.06 | +1.6% | $3.82 | $4.08 | $3.795 | 2,140,800 | |
| $3.83 | -0.04 | -1.0% | $3.82 | $3.915 | $3.72 | 1,696,600 | |
| $3.87 | -0.06 | -1.5% | $3.87 | $3.90 | $3.76 | 2,226,300 | |
| $3.93 | -0.16 | -3.9% | $4.05 | $4.115 | $3.89 | 2,143,500 | |
| $4.09 | -0.07 | -1.7% | $4.16 | $4.215 | $4.07 | 1,719,200 | |
| $4.16 | +0.06 | +1.5% | $4.07 | $4.19 | $4.04 | 2,292,600 | |
| $4.10 | +0.32 | +8.5% | $3.88 | $4.15 | $3.85 | 3,001,200 | |
| $3.78 | -0.13 | -3.3% | $3.89 | $3.89 | $3.71 | 1,924,700 | |
| $3.91 | +0.17 | +4.5% | $3.78 | $4.095 | $3.74 | 2,923,100 | |
| $3.74 | -0.36 | -8.8% | $4.06 | $4.08 | $3.73 | 2,745,700 |
- Ticker
- NASDAQ:SANA
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 5, 2026
Sana Biotechnology Reports Third Quarter 2026 Financial Results and Business Updates
Latest deck · September 2026
Investor Presentation (September 2026)
Investor deck · 29 slides
Latest news
Sana Biotechnology Reports Third Quarter 2026 Financial Results and Business Updates
Nov 5, 2026
Closed $2.37 (+1.3%) on Nov 6, 2026
Sana Biotechnology to Present at September 2026 Investor Conferences
Sep 1, 2026
Closed $3.89 (+1.6%) on Sep 2, 2026
Sana Biotechnology Reports Second Quarter 2026 Financial Results and Business Updates
Aug 10, 2026
Closed $3.79 (+5.0%) on Aug 11, 2026
Sana Biotechnology Announces Follow-On Publication in The New England Journal of Medicine (NEJM) Highlighting Groundbreaking Long-Term Data and Durability of Hypoimmune-Modified Islet Cell Transplantation Without Immunosuppression in Type 1 Diabetes
Jul 13, 2026
Closed $3.64 (-5.5%) on Jul 13, 2026
Sana Biotechnology to Present at June 2026 Investor Conferences
May 27, 2026
Closed $3.13 (+2.3%) on May 28, 2026
Sana Biotechnology Announces Sale of Approximately $69 Million of Shares Through its At-the-Market (ATM) Facility
May 15, 2026
Closed $3.07 (-2.2%) on May 15, 2026
Sana Biotechnology Presents Preclinical Data for In Vivo CAR T Cell Therapy SG293 Surrogate Demonstrating Cell-Specific Delivery, Potent CAR T Cell Generation, and Deep B Cell Depletion in NHPs
May 12, 2026
Closed $3.20 (-1.8%) on May 13, 2026
Sana Biotechnology Reports First Quarter 2026 Financial Results and Business Updates
May 11, 2026
Closed $3.56 (+1.4%) on May 11, 2026
Sana Biotechnology to Present at the BofA Securities 2026 Healthcare Conference
May 5, 2026
Closed $3.64 (+4.3%) on May 6, 2026
Sana Biotechnology, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 18 in the last 12 months · 123 in all · newest Nov 5, 2026 · oldest 2021
- Decks
- 12 decks · latest September 2026
Where Sana Biotechnology, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:SANA · Home listing · This page | NASDAQ | United States | USD |
| BOATS:SANA | BOATS | United States | USD |
Valuation
Price/book 2.6× against a median of 2.3×: 7th lowest of 11 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $408.5M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 2.6×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.3×
- Beta vs S&P 500
- 2.29
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Sana Biotechnology, Inc. · NASDAQ:SANA | US$476.4M | US$408.5M | n/a | n/a | n/a | 2.6× | n/a | 0.3× | 2.29 |
| Steminent Biotherapeutics, Inc. · TPEX:7729 | US$497.0M | US$470.5M | n/a | n/a | n/a | 16.2× | n/a | 0.0× | n/a |
| Xuanzhu Biopharmaceutical Co., Ltd. Class H · HKEX:2575 | US$495.2M | US$407.1M | n/a | 23.2× | n/a | 2.2× | −200.8% | 0.0× | n/a |
| TenNor Therapeutics Suzhou Ltd. Class H · HKEX:6872 | US$489.2M | US$391.6M | n/a | n/a | n/a | 5.0× | n/a | 0.1× | n/a |
| Crescent Biopharma, Inc. · NASDAQ:CBIO | US$482.9M | US$196.0M | n/a | 13.1× | n/a | 1.8× | −727.6% | 0.0× | 0.92 |
| Regenxbio Inc. · NASDAQ:RGNX | US$473.4M | US$289.0M | n/a | 1.9× | n/a | 3.2× | −113.9% | 0.5× | 1.60 |
| Monopar Therapeutics Inc. · NASDAQ:MNPR | US$467.6M | US$362.8M | n/a | n/a | n/a | 3.7× | n/a | 0.0× | 1.18 |
| BlossomHill Therapeutics, Inc. · NASDAQ:BLSM | US$461.2M | US$259.4M | n/a | n/a | n/a | 2.2× | n/a | 0.1× | n/a |
| Neurogene Inc. · NASDAQ:NGNE | US$458.5M | US$106.4M | n/a | n/a | n/a | 1.3× | n/a | 0.0× | 1.47 |
| Assembly Biosciences, Inc. · NASDAQ:ASMB | US$454.4M | US$142.3M | n/a | 2.1× | n/a | 1.5× | −16.6% | 0.0× | 1.00 |
| Shattuck Labs, Inc. · NASDAQ:STTK | US$454.2M | US$260.4M | n/a | n/a | n/a | 2.4× | n/a | 0.0× | 1.10 |
| Median of the others | US$470.5M | US$274.7M | 7.6× | 2.3× | −157.3% | 0.0× | 1.14 |
Forecasts
6 strong buy · 2 buy · 1 hold · Analysts' consensus from EODHD, read Nov 22, 2026. Not 6ix's view and not investment advice.
- Price target
- 8.43 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.50 · 4 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Steve Harr | President and Chief Executive Officer |
| Brian Piper | Executive Vice President, Chief Financial Officer |
| Aaron Grossman | Executive Vice President, Chief Legal Officer |
| Dhavalkumar Patel | Executive Vice President, Chief Scientific Officer |
| Gary Meininger | Executive Vice President, Chief Medical Officer |
| Snehal Patel | Executive Vice President, Chief Technical Officer |
Board
| Director | Role |
|---|---|
| Hans Bishop | Chairman |
| Alise Reicin | Director |
| Josh Bilenker | Director |
| Michelle Seitz | Director |
| Patrick Yang | Director |
| Richard Mulligan | Vice Chairman |
| Rob Rosiello | Director |
| Robert Nelsen | Director |
| Steve Harr | President and Chief Executive Officer |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 5, 2026 · After close | +1.3% |
| Q2 2026 | Aug 10, 2026 · After close | +5.0% |
| Q1 2026 | May 11, 2026 · After close | −8.4% |
| Q4 2025 | Mar 24, 2026 | −0.6% |
| Q3 2025 | Nov 6, 2025 · After close | +1.0% |
| Q2 2025 | Aug 11, 2025 · After close | +6.5% |
| Q1 2025 | May 8, 2025 · After close | +0.6% |
| Q4 2024 | Feb 26, 2025 · Before open | +0.6% |
| Q3 2024 | Nov 8, 2024 · Before open | −3.1% |
| Q2 2024 | Aug 8, 2024 · After close | +5.4% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 8, 2024 · After close | −21.0% |
| Q4 2023 | Feb 29, 2024 · After close | +12.3% |
| Q3 2023 | Nov 8, 2023 · After close | −1.1% |
| Q2 2023 | Aug 3, 2023 · After close | −0.9% |
| Q1 2023 | May 8, 2023 · After close | +10.3% |
| Q4 2022 | Mar 16, 2023 · After close | +7.4% |
| Q3 2022 | Nov 2, 2022 · After close | −13.9% |
| Q2 2022 | Aug 4, 2022 · After close | +11.1% |
| Q1 2022 | May 10, 2022 · After close | −13.5% |
| Q4 2021 | Mar 16, 2022 · Before open | +11.2% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (September 2026) | Investor deck | 29 slides | September 2026 |
| Investor Presentation (January 2026) | Investor deck | 29 slides | Jan 14, 2026 |
| Investor Presentation (January 2025) | Investor deck | 35 slides | Jan 13, 2025 |
| Investor Presentation (January 2024) | Investor deck | 36 slides | Jan 9, 2024 |
| Investor Presentation (December 2023) | Investor deck | 28 slides | Dec 11, 2023 |
| Investor Presentation (October 2023) | Investor deck | 28 slides | Oct 10, 2023 |
| Investor Presentation (September 2023) | Investor deck | 47 slides | Sep 13, 2023 |
| Investor Presentation (June 2023) | Investor deck | 25 slides | Jun 7, 2023 |
| Investor Presentation (January 2023) | Investor deck | 32 slides | Jan 10, 2023 |
| Investor Presentation (June 2022) | Investor deck | 30 slides | Jun 14, 2022 |
All 12 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (January 2022) | Investor deck | 28 slides | Jan 11, 2022 |
| Investor Presentation (September 2021) | Investor deck | 32 slides | Sep 13, 2021 |
Financings
| Raise | Date |
|---|---|
| Strategic investment of equity Announced: strategic investment Buyers: Mayo Clinic | Apr 13, 2026 |
| At-the-market programme of common stock Tranche closed: US$47.4M raised | Mar 3, 2026 |
| Public offering of common stock Closed: US$86.3M raised · US$3.35 a share · Morgan Stanley +3 Dealers: Morgan Stanley (co-lead), Goldman Sachs & Co. LLC (co-lead), BofA Securities (co-lead), TD Cowen (co-lead) | Aug 20, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$25.00 a share on Feb 3, 2021.
- Price
- US$25.00 a share
- Shares offered
- 23,500,000 shares of common stock
- Offering size
- US$587.5 million
- Underwriters' option
- Up to 3,525,000 more shares
- Underwriters
- Morgan Stanley, Goldman Sachs & Co. LLC, J.P. Morgan, BofA Securities · In the order on the cover
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Nov 10, 2020 |
| Filed publicly | Jan 13, 2021 |
| Amended 3 times | Newest Feb 3, 2021 |
| Shares registered with an exchange | Jan 25, 2021 |
| Declared effective by the SEC | Feb 3, 2021 |
| Final prospectus, with the price | Feb 5, 2021 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Feb 5, 2021 |
| EFFECT · Notice that a registration is effective | Feb 3, 2021 |
| S-1MEF · Registration of more shares for the same offering | Feb 3, 2021 |
| CERT · Exchange's certificate of listing | Feb 3, 2021 |
| S-1/A · Registration statement, amended | Feb 3, 2021 |
| S-1/A · Registration statement, amended | Feb 2, 2021 |
| CORRESP · Letter to the SEC | Feb 1, 2021 |
| CORRESP · Letter to the SEC | Jan 28, 2021 |
| S-1/A · Registration statement, amended | Jan 28, 2021 |
| 8-A12B · Registration of shares for listing on an exchange | Jan 25, 2021 |
All 19 filings
| Filing | Filed |
|---|---|
| UPLOAD · Letter from the SEC | Jan 25, 2021 |
| CORRESP · Letter to the SEC | Jan 20, 2021 |
| S-1 · Registration statement | Jan 13, 2021 |
| CORRESP · Letter to the SEC | Jan 12, 2021 |
| UPLOAD · Letter from the SEC | Jan 4, 2021 |
| DRSLTR · Letter to the SEC with a draft | Dec 18, 2020 |
| DRS/A · Draft registration statement, amended | Dec 18, 2020 |
| UPLOAD · Letter from the SEC | Dec 8, 2020 |
| DRS · Draft registration statement | Nov 10, 2020 |
Open IPO · From the cover of the final prospectus (424B4) filed Feb 5, 2021
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Cost of revenue | 12.8M | 15.5M | 30.9M | 27.7M | 17.9M | 10.2M | 3.92M | 1.00K |
| Gross profit | -12.8M | -15.5M | -30.9M | -27.7M | -17.9M | -10.2M | -3.92M | -1.00K |
| Research and development | 132.0M | 215.7M | 261.8M | 285.9M | 248.6M | 132.9M | 99.6M | 4.01M |
| Selling, general and administrative | 44.3M | 64.0M | 73.3M | 71.6M | 50.4M | 28.3M | 21.8M | 8.41M |
| Operating income | -250.3M | -272.7M | -293.1M | -272.6M | -356.9M | -286.1M | -141.2M | -8.22M |
| Depreciation and amortization | 12.8M | 15.5M | 17.5M | 15.6M | 11.1M | 5.92M | 1.83M | 1.00K |
| EBITDA | -237.5M | -257.2M | -275.6M | -257.0M | -345.8M | -280.2M | -139.3M | -8.22M |
| Interest expense | 15.6M | 11.1M | 0 | 2.83M | 0 | |||
| Income before tax | -244.2M | -266.8M | -283.3M | -269.5M | -355.9M | -285.3M | -138.3M | -13.2M |
| Income tax | 0 | -3.09M | -11.7M | -6.67M | -7.55M | |||
| Net income | -244.2M | -266.8M | -283.3M | -269.5M | -355.9M | -285.3M | -130.8M | -13.2M |
| Earnings per share, basic | -0.96 | -1.16 | -1.46 | -1.43 | -2.14 | -21.92 | -26.68 | -0.07 |
| Earnings per share, diluted | -0.96 | -1.16 | -1.46 | -1.43 | -2.14 | -21.92 | -26.68 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 71.9M | 127.6M | 133.5M | 176.8M | 253.0M | 124.8M | 81.8M | 30.6M |
| Short-term investments | 66.5M | 24.9M | 71.7M | 247.2M | 298.0M | 253.5M | 59.0M | 0 |
| Current assets | 148.7M | 160.8M | 213.5M | 444.4M | 558.1M | 384.5M | 144.3M | 32.6M |
| Property, plant and equipment | 26.9M | 77.3M | 70.7M | 66.9M | 65.5M | 46.8M | 68.8M | 585.0K |
| Goodwill | 140.6M | 140.6M | 140.6M | 140.6M | 140.6M | 140.6M | 140.6M | 0 |
| Total assets | 416.9M | 501.0M | 565.3M | 822.7M | 1.13B | 730.3M | 415.2M | 34.3M |
| Accounts payable | 1.67M | 5.21M | 4.11M | 2.86M | 2.22M | 2.25M | 0 | 289.0K |
| Current liabilities | 78.7M | 45.4M | 64.5M | 111.5M | 99.2M | 31.5M | 19.3M | 1.78M |
| Total debt | 78.9M | 94.2M | 104.1M | 108.3M | 110.9M | 71.9M | 47.7M | |
| Total liabilities | 256.0M | 250.5M | 277.8M | 323.4M | 400.9M | 298.6M | 557.7M | 47.5M |
| Shareholders' equity | 160.9M | 250.5M | 287.5M | 499.3M | 728.5M | -421.2M | -142.5M | -13.2M |
| Shares outstanding | 266.7M | 223.9M | 197.9M | 191.0M | 184.9M | 16.2M | 191.4M | 187.3M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -143.8M | -223.2M | -253.6M | -290.1M | -251.1M | -138.0M | -85.5M | -13.5M |
| Capital spending | -938.0K | -33.4M | -20.0M | -20.9M | -29.9M | -23.9M | -26.1M | -460.0K |
| Free cash flow | -144.8M | -256.6M | -273.6M | -310.9M | -280.9M | -161.9M | -111.6M | -14.0M |
| Cash from investing | -40.2M | 17.5M | 172.0M | 210.6M | -245.8M | -252.6M | -87.9M | -780.0K |
| Cash from financing | 128.7M | 199.7M | 31.6M | 4.91M | 631.8M | 435.7M | 223.7M | 45.7M |
| Share buybacks | 601.0K | 626.4M | ||||||
| Change in cash | -55.3M | -5.95M | -49.9M | -74.6M | 134.9M | 45.1M | 50.4M | 31.4M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | Nov 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 5, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 5, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 6, 2026 | Insider trade | SEC |
| 8-K · Current report | Sep 8, 2026 | Current report | SEC |
| 4 · Change in ownership | Aug 27, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 10, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 10, 2026 | Results | SEC |
| 4 · Change in ownership | Jul 7, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 5, 2026 | Meeting outcome | SEC |
| SCHEDULE 13G · Big-stake notice | May 21, 2026 | Big-stake notice | SEC |
| 8-K · Current report | May 15, 2026 | Current report | SEC |
| S-8 · Registration statement for employee plans | May 11, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | May 11, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 11, 2026 | Results | SEC |
| ARS · Annual report to shareholders | Apr 24, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 24, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 24, 2026 | Meeting notice | SEC |
| 8-K · Current report | Apr 24, 2026 | Management or board change | SEC |
| 424B5 · Prospectus | Apr 13, 2026 | Offer document | SEC |
| 8-K · Current report | Apr 13, 2026 | Current report | SEC |
| 4 · Change in ownership | Apr 8, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2026 | Insider trade | SEC |
| S-3ASR · Registration statement | Mar 3, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 3, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 3, 2026 | Results | SEC |
| 4 · Change in ownership | Feb 18, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 18, 2026 | Insider trade | SEC |
| 8-K · Current report | Feb 17, 2026 | Management or board change | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 21, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jan 14, 2026 | Current report | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Dec 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 5, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 6, 2025 | Results | SEC |
| 4 · Change in ownership | Oct 7, 2025 | Insider trade | SEC |
| UPLOAD · Letter from the SEC | Sep 10, 2025 | Other filings | SEC |
| 8-K · Current report | Sep 5, 2025 | Management or board change | SEC |
| 8-K · Current report | Aug 29, 2025 | Management or board change | SEC |
| CORRESP · Letter to the SEC | Aug 13, 2025 | Other filings | SEC |
| 10-Q · Quarterly report | Aug 11, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 11, 2025 | Results | SEC |
| 8-K · Current report | Aug 7, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Aug 7, 2025 | Offer document | SEC |
| 424B5 · Prospectus | Aug 6, 2025 | Offer document | SEC |
| 8-K · Current report | Aug 6, 2025 | Results | SEC |
| UPLOAD · Letter from the SEC | Jul 30, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jul 8, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 23, 2025 | Current report | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 9, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 6, 2025 | Meeting outcome | SEC |
| 424B5 · Prospectus | May 8, 2025 | Offer document | SEC |
| S-8 · Registration statement for employee plans | May 8, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | May 8, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 8, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 25, 2025 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | Apr 25, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 25, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 25, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 8, 2025 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Mar 24, 2025 | Other filings | SEC |
| POS AM · Amendment to an effective registration | Mar 17, 2025 | Offer document | SEC |
| 10-K · Annual report | Mar 17, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 17, 2025 | Results | SEC |
| POSASR | Mar 14, 2025 | Other filings | SEC |
| 4 · Change in ownership | Mar 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 18, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 31, 2025 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Jan 16, 2025 | Other filings | SEC |
| 8-K · Current report | Jan 13, 2025 | Current report | SEC |
| 4 · Change in ownership | Jan 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 16, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 26, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 25, 2024 | Other filings | SEC |
| 3/A · Initial statement of ownership, amended | Nov 21, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 12, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 12, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Nov 8, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 8, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 8, 2024 | Results | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 4, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Oct 22, 2024 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Oct 21, 2024 | Other filings | SEC |
| 3 · Initial statement of ownership | Oct 15, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 9, 2024 | Insider trade | SEC |
| 8-K · Current report | Oct 8, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Sep 26, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 25, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 24, 2024 | Other filings | SEC |
| 8-K · Current report | Sep 12, 2024 | Management or board change | SEC |
| 10-Q · Quarterly report | Aug 8, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 8, 2024 | Results | SEC |
| 4/A · Change in ownership, amended | Jul 15, 2024 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Jul 15, 2024 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Jul 15, 2024 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Jul 15, 2024 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Jul 15, 2024 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Jul 15, 2024 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Jul 15, 2024 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Jul 15, 2024 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Jul 15, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 8, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 7, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 7, 2024 | Meeting outcome | SEC |
| S-8 · Registration statement for employee plans | May 8, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | May 8, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 8, 2024 | Results | SEC |
| ARS · Annual report to shareholders | Apr 26, 2024 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 26, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 26, 2024 | Meeting notice | SEC |
| 8-K · Current report | Apr 18, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Apr 8, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 8, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Apr 3, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 8, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 8, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 8, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 8, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 8, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Mar 7, 2024 | Big-stake notice | SEC |
| S-3ASR · Registration statement | Mar 1, 2024 | Offer document | SEC |
| 10-K · Annual report | Feb 29, 2024 | Annual report | SEC |
| 8-K · Current report | Feb 29, 2024 | Results | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 14, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 12, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 9, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 9, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Feb 8, 2024 | Material contract | SEC |
| 424B5 · Prospectus | Feb 8, 2024 | Offer document | SEC |
| FWP · Free writing prospectus | Feb 7, 2024 | Offer document | SEC |
| 424B5 · Prospectus | Feb 7, 2024 | Offer document | SEC |
| 8-K · Current report | Feb 7, 2024 | Results | SEC |
| SC 13G/A · Big-stake notice, amended | Jan 26, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Jan 9, 2024 | Current report | SEC |
| 4 · Change in ownership | Jan 8, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 8, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 18, 2023 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 15, 2023 | Other filings | SEC |
| 8-K · Current report | Dec 11, 2023 | Current report | SEC |
| 10-Q · Quarterly report | Nov 8, 2023 | Quarterly report | SEC |
| 8-K · Current report | Nov 8, 2023 | Results | SEC |
| 4 · Change in ownership | Nov 3, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Nov 3, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Nov 3, 2023 | Insider trade | SEC |
| 8-K · Current report | Oct 10, 2023 | Current report | SEC |
| 4 · Change in ownership | Oct 6, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Oct 6, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Sep 15, 2023 | Insider trade | SEC |
| 8-K · Current report | Sep 13, 2023 | Current report | SEC |
| 8-K · Current report | Aug 21, 2023 | Current report | SEC |
| 10-Q · Quarterly report | Aug 3, 2023 | Quarterly report | SEC |
| 8-K · Current report | Aug 3, 2023 | Results | SEC |
| 4 · Change in ownership | Jul 6, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 6, 2023 | Insider trade | SEC |
This page holds 200 of 392 filings. Open Filings
Cap table
Built by 6ix from Sana Biotechnology, Inc.’s releases · as of Oct 29, 2026
- Common shares
- 299,634,951
- Fully diluted
- 299,634,951
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 299,634,951 | Oct 29, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Oct 29, 2026 | 299,634,951 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Robert Nelsen Other companies: City Therapeutics, Inc. (Board Director · Since at least Oct 19, 2026); Kardigan, Inc. (Director · Since at least Jun 22, 2026); Metsera, Inc. (Director · Since at least Nov 13, 2025); Prime Medicine, Inc. (Board Member · Since at least Oct 19, 2022); Lyell Immunopharma, Inc. (Director · Jun 16, 2021 – Jun 14, 2024 · Past); Revolution Healthcare Acquisition Corp (Director · Mar 17, 2021 – Mar 17, 2021 · Past); Beam Therapeutics Inc. (Director · Feb 5, 2020 – Mar 31, 2021 · Past); Vir Biotechnology, Inc. (Director · Oct 10, 2019 – May 30, 2024 · Past); Karuna Therapeutics Inc (Director · Jun 27, 2019 – Apr 13, 2021 · Past); Unity Biotechnology Inc (Director · May 2, 2018 – Jun 18, 2020 · Past); Denali Therapeutics Inc. (Director · Dec 7, 2017 – Jun 2, 2021 · Past); Syros Pharmaceuticals, Inc. (Director · Jun 29, 2016 – Jun 8, 2017 · Past); Bellerophon Therapeutics Inc (Director · Feb 12, 2015 – Feb 13, 2015 · Past); Juno Therapeutics Inc (Director · Dec 18, 2014 – Mar 5, 2018 · Past); Sage Therapeutics Inc (Director · Jul 17, 2014 – Nov 9, 2015 · Past); Fate Therapeutics, Inc. (Director · Sep 30, 2013 – Oct 4, 2013 · Past); Agios Pharmaceuticals, Inc. (Director · Jul 23, 2013 – Mar 3, 2017 · Past); Kythera Biopharmaceuticals Inc (Director · Oct 10, 2012 – Aug 14, 2014 · Past); NeurogesX Inc (Director · May 1, 2007 – Jun 7, 2012 · Past); Adolor Corp (Director · May 18, 2006 – May 17, 2007 · Past) | Director · Since at least Feb 3, 2021 |
| Mary Agnes Wilderotter Other companies: Okta, Inc. (Director · Since at least Aug 13, 2025); Fortinet, Inc. (Director · Since at least Apr 19, 2024); DocuSign, Inc. (Director · Since at least Apr 26, 2018); Costco Wholesale Corporation (Director · Since at least Oct 13, 2015); Lyft, Inc. (Director · Mar 28, 2019 – Aug 28, 2023 · Past); Cadence Design Systems, Inc. (Director · Jul 1, 2017 – Feb 14, 2020 · Past); DXC Technology Company (Director · Mar 15, 2017 – Mar 15, 2017 · Past); Hewlett Packard Enterprise Company (Director · Feb 10, 2016 – Apr 5, 2022 · Past); Dreamworks Animation SKG Inc (Director · Oct 22, 2015 – Aug 22, 2016 · Past); Juno Therapeutics Inc (Director · Dec 18, 2014 – Mar 5, 2018 · Past); Procter & Gamble Company (the) (Director · Aug 11, 2009 – Oct 15, 2015 · Past); Frontier Communications Corporation (Executive Chairman, Director · Nov 3, 2008 – Feb 26, 2016 · Past); Altaba Inc (Director · Jul 26, 2007 – Jun 25, 2009 · Past); The McClatchy Company (Director · May 17, 2006 – May 16, 2007 · Past); Xerox Holdings Corporation (Director · Mar 1, 2006 – Jul 15, 2015 · Past) | Director · Since at least Feb 3, 2021 |
| Douglas E. Williams Other companies: CAMP4 Therapeutics Corporation (Chairman of the Board · Since at least Mar 17, 2025); Climb Bio, Inc. (Chairman · Since at least Nov 8, 2024); Panacea Acquisition II Corp (Director · Apr 6, 2021 – Apr 6, 2021 · Past); Codiak BioSciences Inc (President & CEO, Director · Oct 13, 2020 – Mar 28, 2023 · Past); Ovid Therapeutics Inc. (Director · May 4, 2017 – May 17, 2021 · Past); Ironwood Pharmaceuticals, Inc. (Director · Jun 3, 2014 – Apr 1, 2019 · Past); Regulus Therapeutics Inc (Director · Nov 5, 2012 – Jun 2, 2016 · Past); Biogen Inc. (EVP Research & Development · Jan 10, 2011 – Jun 19, 2015 · Past); Cascadian Therapeutics Inc (Director · Oct 1, 2009 – Jun 13, 2013 · Past); Anadys Pharmaceuticals Inc (Director · Jun 2, 2006 – May 30, 2008 · Past) | EVP & President, R&D · Apr 10, 2023 – Mar 7, 2024 · Past |
| Douglas G Cole Other companies: Foghorn Therapeutics Inc. (Director · Since at least Oct 22, 2020); Sigilon Therapeutics Inc (Director · Dec 3, 2020 – Aug 11, 2023 · Past); Denali Therapeutics Inc. (Director · Dec 7, 2017 – Jun 1, 2023 · Past); Quanterix Corporation (Director · Dec 6, 2017 – Jan 2, 2019 · Past); Editas Medicine, Inc. (Director · Feb 2, 2016 – Aug 17, 2017 · Past); Agios Pharmaceuticals, Inc. (Director · Jul 23, 2013 – Aug 10, 2016 · Past); Receptos Inc (Director · May 8, 2013 – Jul 17, 2013 · Past); Tetraphase Pharmaceuticals Inc (Director · Mar 19, 2013 – Mar 25, 2013 · Past); AVEO Pharmaceuticals Inc (Director · Mar 11, 2010 – May 12, 2011 · Past) | Director · Feb 3, 2021 – Jun 6, 2024 · Past |
| Sunil Agarwal Other companies: Astria Therapeutics Inc (Director · Since at least Apr 5, 2024); Arvinas, Inc. (Director · Since at least Jun 15, 2023); Juno Therapeutics Inc (President of R & D · Apr 13, 2017 – Mar 5, 2018 · Past); MyoKardia Inc (Director · Mar 4, 2016 – Nov 17, 2020 · Past); Calithera Biosciences, Inc. (Director · Sep 29, 2015 – Jun 1, 2022 · Past); Ultragenyx Pharmaceutical Inc. (Chief Medical Officer · Aug 19, 2015 – Aug 19, 2016 · Past) | EVP, Head of Development & CMO · Feb 3, 2021 – Mar 3, 2022 · Past |
| Patrick Yang Other companies: Amyris Inc (Director · Jul 1, 2014 – Aug 5, 2020 · Past); Eiger Biopharmaceuticals Inc (Director · Mar 2, 2014 – May 20, 2014 · Past); Codexis, Inc. (Director · Feb 22, 2014 – Jun 14, 2022 · Past); Andeavor (Director · Dec 8, 2010 – Oct 1, 2018 · Past); Genentech Inc (EVP, Product Operations · Mar 26, 2009 – Mar 26, 2009 · Past) | Director · Since at least Feb 3, 2021 |
| Robert L Rosiello Other companies: Seres Therapeutics, Inc. (Director · Since at least Aug 5, 2025); Omega Therapeutics Inc (Director · Oct 2, 2024 – Oct 2, 2024 · Past); Evelo Biosciences, Inc. (Director · Apr 14, 2023 – Jun 8, 2023 · Past); Axcella Health Inc (Director · Oct 10, 2022 – Nov 16, 2022 · Past); Bausch Health Companies Inc. (EVP, Corp Dev & Strategy · Jun 11, 2015 – Dec 5, 2016 · Past) | Director · Since at least Jun 5, 2025 |
| Alise Reicin Other companies: Immatics N.V. (Director · Since at least Mar 18, 2026); Tectonic Therapeutic, Inc. (President and CEO, Director · Since at least Jun 20, 2024); Q32 Bio Inc. (Director · Jul 11, 2019 – Jun 14, 2023 · Past); Celgene Corporation (PRES., GLOBAL CLINICAL DEV. · Nov 1, 2018 – Nov 20, 2019 · Past) | Director · Since at least Feb 3, 2021 |
| Hans Bishop Other companies: Lyell Immunopharma, Inc. (Director · Jun 16, 2021 – Jun 14, 2024 · Past); Celgene Corporation (Director · Apr 18, 2018 – Nov 20, 2019 · Past); Agilent Technologies, Inc. (Director · Jul 18, 2017 – Mar 15, 2024 · Past); Juno Therapeutics Inc (CEO & President, Director · Jun 9, 2016 – Mar 5, 2018 · Past) | Chairman · Since at least Feb 3, 2021 |
| Joshua H Bilenker Other companies: Gossamer Bio, Inc. (Director · Feb 7, 2019 – Jun 9, 2022 · Past); T2 Biosystems, Inc. (Director · Aug 6, 2014 – Jun 17, 2016 · Past); Loxo Oncology Inc (President & CEO, Director · Jul 31, 2014 – Feb 15, 2019 · Past); Roka Bioscience Inc (Director · Jul 16, 2014 – Jul 16, 2014 · Past) | Director · Since at least Feb 3, 2021 |
All 28 people
| Person | Seat |
|---|---|
| Richard Mulligan Other companies: International Flavors & Fragrances, Inc. (Director · Since at least Oct 20, 2025); Bausch Health Companies Inc. (Director · May 10, 2022 – May 16, 2025 · Past); Biogen Inc. (Director · Jun 10, 2009 – Jun 15, 2022 · Past); Viskase Holdings, Inc. (Director · May 21, 2009 – Jan 2, 2013 · Past) | Vice Chairman · Since at least Feb 3, 2021 |
| Bernard J Cassidy Other companies: Juno Therapeutics Inc (General Counsel & Secretary · Dec 18, 2014 – Mar 5, 2018 · Past); Tessera Technologies Inc (EVP & GC, TIPC President · Nov 17, 2008 – Mar 6, 2013 · Past); Tumbleweed Communications Corp (SVP,General Counsel &Secretary · Apr 24, 2007 – Sep 3, 2008 · Past) | EVP & General Counsel · Sep 12, 2022 – Mar 6, 2025 · Past |
| Michelle Seitz Other companies: Honeywell Aerospace Inc (Director · Since at least Jun 29, 2026); MetLife, Inc. (Director · Since at least Feb 24, 2026); MSCI Inc. (Director · Since at least Aug 5, 2024) | Director · Since at least Feb 3, 2021 |
| Brian Piper Other companies: Prelude Therapeutics Incorporated (Chief Financial Officer · Sep 24, 2020 – Aug 25, 2021 · Past); Aevi Genomic Medicine LLC (CFO & Corporate Secretary · Feb 9, 2016 – Jun 14, 2018 · Past) | Executive Vice President, Chief Financial Officer · Since at least Feb 17, 2026 |
| Steve Harr Other companies: Loxo Oncology Inc (Director · Nov 7, 2016 – Feb 15, 2019 · Past); Juno Therapeutics Inc (CFO & Head, Corp. Development · Dec 18, 2014 – Mar 5, 2018 · Past) | President & CEO, Director · Since at least Feb 3, 2021 |
| Geoffrey von Maltzahn Other companies: Kaleido Biosciences, Inc. (Director · Feb 27, 2019 – Jun 30, 2021 · Past) | Director · Feb 3, 2021 – Feb 8, 2021 · Past |
| Susan D Wyrick Other companies: Achieve Life Sciences, Inc. (PAO · Feb 1, 2013 – Mar 14, 2014 · Past) | See Remarks · Since at least Oct 4, 2024 |
| Aaron Grossman | Executive Vice President, Chief Legal Officer · Since at least Nov 4, 2026 |
| Christian Hordo | EVP, Chief Business Officer · Feb 3, 2021 – Mar 7, 2024 · Past |
| Dhavalkumar Patel | Executive Vice President, Chief Scientific Officer · Since at least Mar 24, 2026 |
| Gary Meininger | Executive Vice President, Chief Medical Officer · Since at least Jul 13, 2026 |
| James J MacDonald | EVP & General Counsel · Feb 3, 2021 – Jun 13, 2022 · Past |
| Jim MacDonald | Chief Executive Officer and member of its Board of Directors · Sep 16, 2025 – Nov 4, 2026 · Past |
| Josh Bilenker | Director · Since at least Nov 4, 2026 |
| Nathan Hardy | EVP, Chief Financial Officer · Feb 3, 2021 – Mar 7, 2024 · Past |
| Rob Rosiello | Director · Since at least Nov 4, 2026 |
| Snehal Patel | Executive Vice President, Chief Technical Officer · Since at least Nov 4, 2026 |
| Steve Harr | President and Chief Executive Officer · Since at least Aug 10, 2026 |
Log in to ask 6ix AI your own questions about Sana Biotechnology, Inc.